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CASE REPORT
Erythropoietin combined with parenteral iron sucrose therapy is an alternative to blood transfusion in anemic
patients. It was shown to be effective in surgical patients in several previous studies when used in conjunction with
other methods. However, there are no guidelines about safety limits in dosage amounts or intervals. In this study,
we report a case of significant postoperative hemorrhage managed with high dose parenteral iron sucrose, low
dose erythropoietin, vitamin B12, vitamin C, and folic acid. An 80-year-old female patient presented for severe
anemia after a total hip arthroplasty and refused an allogenic blood transfusion as treatment. The preoperative
hemoglobin of 12.2 g/dL decreased to 5.3 g/dL postoperatively. She received the aforementioned combination of
iron sucrose, erythropoietin, and vitamins. A total of 1,500 mg of intravenous iron sucrose was given
postoperatively for 6 consecutive days. Erythropoietin was also administered at 2,000 IU every other day for a
total of 12,000 IU. The patient was discharged in good condition on the twelfth postoperative day with a
hemoglobin of 8.5 g/dL. Her hemoglobin was at 11.2 g/dL on the twentieth postoperative day. (Korean J Intern
Med 2010;25:454-457)
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INTRODUCTION
Allogenic blood transfusion (ABT) is a life-saving procedure
in many clinical situations.  However, ABT can result in
unpredictable clinical consequences and risks despite
technical improvements to reduce such problems [1]. A study
evaluated transfusion management procedures in elective
orthopedic surgeries, particularly hip and knee arthoplasties,
and identified the benefits of autologous blood transfusions
over ABT [2]. Several recent reports have indicated that
perioperative erythropoietin in conjunction with intravenous
iron sucrose supplementation is an effective alternative to
ABT [3,4]. However, there are no guidelines for its dosage and
safety limits. Preoperative autologous blood donation with
high dose erythropoietin, although clinically optimal, is quite
costly [5] Further, individual perioperative blood loss is
unpredictable and therefore concerns regarding the cost-
effectiveness and the safety of autologous blood donations
exist. We present a case in which we managed unexpected
and severe bleeding after a total hip replacement arthroplasty
(THR) without a blood transfusion.  We used a combination
of high dose intravenous iron sucrose and moderate to low
doses of erythropoietin as previously described [3,4,6,7].
Postoperative management was used exclusively in this case. 
CASE REPORT 
An 80-year-old woman presented to our clinic with
intractable left hip pain and magnetic resonance imaging
(MRI) revealed avascular necrosis of the femoral head. A total
hip arthroplasty was recommended. The patient refused to
donate blood for an autologous blood transfusion as a result
of her religious beliefs.  Her past medical history wasYoon J, et al. Postoperative intravenous iron sucrose with erythropoietin    455
unremarkable. Physical examination was within normal
limits except for left hip tenderness. Preoperative hemoglobin
was 12.2 g/dL. Other laboratory results including complete
blood count, aspartate aminotransferase, alanine
transaminase, blood urea nitrogen, creatinine, prothrombin
time and activated partial thromboplastin time were all within
normal range. A chest radiograph showed left pleural
adhesions and regional parenchymal fibrotic changes, which
were most likely sequelae from prior pulmonary tuberculosis.
Arterial blood gas measurements and pulmonary function
test results were within normal limits. Electrocardiogram , 2-
D echocardiography, and carotid Doppler studies revealed no
significant findings except for aging changes in the aortic valve
and relaxation abnormalities. Despite her age, elective total
hip arthroplasty was scheduled because of her good general
health, lack of anemia, and lack of risk factors contributing to
ischemic complications. Aprotinin was administered
perioperatively from the procedure induction to 6 hours
postoperatively until there was no significant drainage from
the surgical site. However, massive blood loss put the patient
in a hypovolemic and hypotensive status postoperatively
despite efforts to minimize bleeding. Postoperative
hemoglobin decreased to 6.4 g/dL from the preoperative
measurement of 12.2 g/dL. The patient refused an allogenic
blood transfusion and therefore intravenous iron sucrose
(Venoferum
®, Choongwoe Co., Seoul, Korea) administration
was initiated. A dose of 100 mg of iron sucrose diluted in 100
mL of normal saline was administered intravenously over 1
hour twice per day up to 700 mg of cumulative dosage from
the day of surgery to the third postoperative day. Additionally,
2,000 IU of recombinant erythropoietin (Recormon
®,
Choongwoe Co.) was injected every other day with a daily
supply of iron sucrose vitamin B12, vitamin C, and folic acid.
Dalteparin was administered at a dose of 5,000 IU per day to
prevent deep vein thrombosis. Hemoglobin level decreased to
5.3 g/dL on the fourth postoperative day (Table 1). Further
injection of 200 mg of iron sucrose in 200 mL of normal
saline was administered twice per day on the fourth and fifth
postoperative days. A total of 1,500 mg of iron sucrose was
administered intravenously for 6 consecutive days. The
patient complained of mild chest discomfort and dyspnea
after the last dose of iron sucrose, and this was most likely a
side effect of intravenous iron sucrose which resolved with a
50 mg hydrocortisone injection. On the seventh postoperative
day, the patient had a hemoglobin of 6.4 g/dL on and was
able to walk with assistance. There were no significant
complications or residual side effects of high dose intravenous
iron sucrose or erythropoietin therapy. The final dose of
erythropoietin was administered on the twelfth postoperative
day with a hemoglobin of 8.5 g/dL (Fig. 1), a corrected
reticulocyte count of 2.64%, a transferrin saturation of 30%,
and a ferritin level of 906 ng/mL. Total dose of erythropoietin
was 12,000 IU which was equivalent to 40 IU/kg for a single
dose and 240 IU/kg for the cumulative dose. The patient was
discharged in good condition with oral doses of vitamin B12,
vitamin C and folic acid. The patient presented for follow-up
on the twentieth postoperative day with a hemoglobin of 11.2
g/dL and no clinical complications. 
Figure 1.  Changes of the level of hemoglobin following
postoperative high-dose intravenous iron sucrose with
erythropoietic therapy after total hip replacement. Intravenous
iron sucrose was given at postoperative day 0, 1, 2, 3, 4, 5 and
erythropoietin was injected at postoperative day 1, 3, 5, 7, 9, 11.
OP, operation; arrow head, erythropoietin; arrow, intravenous
iron sucrose injection.
Table 1. Laboratory results with dosages of intravenous iron sucrose and erythropoietin during postoperative period
Postoperative day -1
a 0 1 2 3 4 5 7 9 11 12 20
IV iron sucrose, mg 100 200 200 200 400 400
EPO, IU 2,000 2,000 2,000 2,000 2,000 2,000
Hemoglobin, g/dL 12.2 6.4 5.9 5.9 5.6 5.3 5.9 6.4 8.1 8.5 11.2
Hematocrit, % 34.2 18 16.2 15.5 15.2 14.9 16.2 17.6 22.7 23.3 32.3
MCV, fL 93.8 93.5 93.3 92.8 92.9 94.1 94.5 98.5 101 103 105.0
MCH, pg/cell 33.5 33.3 34.1 35.2 34.4 33.4 34.3 35.9 36.1 37.4 36.5
IV, intravenous; EPO, erythropoietin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin.
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DISCUSSION
Studies have demonstrated the safety of intravenous iron
sucrose over intravenous iron sucrose dextran [8]. The
dextran molecule, which acts as a carbohydrate antigen,
causes severe transfusion reactions and even fatalities. This
limits the use of iron sucrose dextran in the clinical setting [9].
Recent reports have suggested the role of perioperative
intravenous iron sucrose in enhancing the safety of allogenic
blood transfusions [3,4]. Intravenous iron sucrose doses did
not exceed 400 mg perioperatively with single injection doses
of erythropoietin as high as 40,000 IU in previous studies.
We reported relatively high doses of parenteral iron sucrose
and low doses of erythropoietin in the management of an
anemic patient who refused an allogenic blood transfusion.
The typical dose of parenteral iron sucrose can be as high as
200 mg without significant side effects in surgical or dialysis
patients [3,4,10] and these patients received recombinant
erythropoietin at single doses of 300 IU/kg or cumulative
doses of 40,000 IU/wk [11]. Clinical conditions such as
inflammation result in inadequate erythropoietin production
and function. However, additional reservoirs of
erythropoietin in the patient with normal renal function are
stimulated in hypoxic conditions. Therefore, conditions which
result in relative erythropoietin deficiency might benefit from
the administration of low dose erythropoietin. This low dose
erythropoietin could correct anemia and prove to be cost-
effective with an adequate supplement of available iron
sucrose in the acute clinical setting. Erythropoietin
administration is more costly than parenteral iron sucrose
among alternatives for ABT. 
The inflammatory status of the postoperative patient affects
iron sucrose metabolism and is mediated by several
cytokines. The cytokine hepcidin, which is important in
familial hemochromatosis, plays a chief role in the
impairment of iron sucrose utilization in the clinical setting
[12]. Hepcidin is a synthesized by hepatocytes and stimulated
by inflammation or iron sucrose overload. It is a negative
regulator for both iron sucrose absorption in the gut and iron
sucrose release from macrophages [13] in its role in anemia of
chronic illness. Physiologic reduction of serum iron sucrose
could serve as a protective strategy against bacteria since
limitation of available iron sucrose creates an inhospitable
environment in bacterial infection. However, hepcidin limits
iron sucrose utilization and enhances iron sequestration, and
therefore baseline exogenous iron supplementation would
not result in adequate levels of available iron for bone marrow
erythropoiesis, particularly if stimulated by exogenous
erythropoietin. Further, both decreased gut absorption of iron
and sequestration of iron mediated by hepcidin suggest a
particular benefit of parenteral iron as compared with oral
iron supplementation. 
Erythropoietin accelerates the erythropoiesis in its role as
an anti-apoptotic cytokine and is involved in protection
against ischemic insults including strokes or renal injuries.
Erythropoietin receptors are located in the bone marrow,
heart, brain, and kidney [14], which explains the non-
hematologic effects of erythropoietin. Its protective effects in
trauma patients is documented in a large randomized study
[15]. However, the routine administration of erythropoietin in
critical patients is still controversial [16].
There may be a role for erythropoietin in the management
of the hypovolemic and ischemic patients because of its
protective and anti-ischemic activity [17]. Erythropoietin
could serve as a bridge to maintain hematocrit from the time
gap between blood loss and hemoglobin increase. Although it
is not indicated in general critical cases, it may have a role as
an adjunct therapy in the management of the anemic patient
to reduce the rate of ABT.
Folic acid and vitamin B12 are essential in rapid
erythropoiesis. Vitamin C has an active role in the release of
sequestrated iron from reticuloendothelial cells and therefore
facilitates the erythropoietin response. Favorable effects of
parenteral iron treatment combined with vitamin C
administration also suggest that vitamin C contributes to
decreased oxidative stress as an antioxidant, may reduce iron-
overload toxicity, and may decrease the total body iron
requirement [18]. We believe that the administration of
vitamin C in our patient, even at a minimal dosage,
contributed to accelerated hematopoiesis.
Aprotinin was used in this case study instead of a
perioperative blood salvage system. Aprotinin is a polypeptide
extracted from bovine lung tisse and has anti-fibrinolytic and
anti-kallikrein activity. There are several reports revealing the
efficacy and safety of aprotinin in orthopedic surgeries [19].
However, its association with thrombosis and renal failure
limits its use in clinical practice.
There are several alternatives to ABT in clinical case
management. Preoperative autologous blood donation,
perioperative blood salvage systems, and intraoperative
hemodilution all serve to reduce the ABT rate in major
orthopedic surgeries [20]. However, the patient in this case
report refused all blood products and, as a result, all of the
aforementioned procedures. Preoperative erythropoietin with
intravenous iron sucrose without autologous blood donation
would have been the primary option in this case. Yoon J, et al. Postoperative intravenous iron sucrose with erythropoietin    457
In conclusion, aggressive high dose intravenous iron
sucrose with low dose erythropoietin was successful in our
postoperative management of a severely anemic patient.
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